



Dr. RuiRong Yuan is an US-board certified medical oncologist and attending physician at Department of Medicine, VA Medical Center of New Jersey Medical School. She previously served as Chief Medical Officer & President of global clinical development at BeiGene. Before that, Dr. Yuan was Chief Medical Officer and Vice President of Eisai Global Oncology, Head of multiple therapeutic areas at Daiichi Sankyo and senior global clinical leader at Novartis Oncology. Dr. Yuan led global clinical research & development divisions in conducting early

and late global clinical studies and played a critical leadership role in the development, regulatory approval and commercialization of multiple compounds, including anti-cancer drug Afinitor, Zelboraf, Lenvatinib and Halaven.

Dr. Yuan has had extensive academic clinical practice and research experience as a physician-scientist at top cancer centers in Asian (Cancer hospital, Chinese Academy of Medical Sciences), Europe (Oncology Institute of Southern Switzerland) and the US (AECOM, MSKCC, UMDNJ). She has published more than thirty peer reviewed original research articles, including publications in *Journal Experimental Medicine*, *Blood*, *Journal of Immunology*, *PNAS*, *British J. Cancer*, *Cancer Research*, *Annals of Neurology* and *Neurotherapeutics*. She holds multiple patents related to either cancer treatment or autoimmune disease therapy.

Dr. Yuan is one of the founding members of Chinese American Hematologist and Oncologist Network (www.cahon.org) and served as its president in 2007-2008 and Board chair in 2010-2012. She has been an executive member of the Chinese Society of Clinical Oncology (CSCO) since 2004 and served on the ASCO-International Affairs committee from July 2006 to June 2009. She also serves as editor for multiple Journals of hematology and Oncology.

袁瑞荣医学博士，现任美国新泽西医科大学附属医院VA Medical Center 临床肿瘤及血液内科主治医师。她长期从事肿瘤和自身免疫性疾病的临床及转化性研究，是美国认证的内科和肿瘤内科专家。曾担任百济神州首席医学官兼全球临床开发部总裁，Eisai(卫材)首席医学官兼副总裁，第一三共株式会社多个治疗领域负责人和诺华肿瘤部全球临床研究负责人，主持或领导了多项国际临床抗肿瘤新药，其中包括Afinitor，Zelboraf，Lenvatinib和Halaven的研究，监管部门的批准和商业化。

袁瑞荣博士1983年毕业于山东医科大学医学系，继在中国医学科学院肿瘤医院孙燕教授指导下完成了临床肿瘤内科学和免疫学(临床医学博士)训练。1989年赴瑞士伯尔尼大学从事肿瘤临床及分子生物学研究，并获得瑞士癌症研究国家奖和伯尔尼大学博士学位(导师:Prof. Franco Cavalli)。1993年赴美国先后在爱因斯坦大学医学院和纪念斯隆凯特林癌症中心从事免疫学、内科学、血液及肿瘤临床专科研究。曾任美国新泽西医学及口腔医学大学新泽西医学院肿瘤免疫学和神经免疫学实验室主任及博士后导师，拥有与癌症和自身免疫性疾病治疗有关的多项专利。

袁医生积极参与并促进中国与国外癌症研究方面的合作，任中国肿瘤临床协会(CSCO)来自海外的执行委员多年，曾多次应邀回国作学术访问。她曾担任旅美华人血液和肿瘤专科医师学会(CAHON)会长和董事会主席，ASCO国际委员会委员(2005-2008)，山东大学客座教授及多个医学期刊编委。